Wednesday, July 8, 2026

Patent intelligence · US

US 11172694

Core-shell structure with titanium dioxide core

granted A61KA61K33/00A61K33/30A61K9/5015
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 15
Applicant portfolio 2
Patent details — US 11172694
Jurisdiction
US
Status
granted
Grant date
Nov 16, 2021
Expiration
Nov 11, 2041
Claims
14
CPC classes
A61K, A61K33/00, A61K33/30, A61K9/5015
View on Google Patents ↗

Quick answer

US 11172694 (Core-shell structure with titanium dioxide core) is held by SOLID CHEMICALS GMBH. Status: granted. Granted Nov 16, 2021. Expires Nov 11, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
14
CPC classes
A61K, A61K33/00, A61K33/30, A61K9/5015, A61P, A61P1/12

More from SOLID CHEMICALS GMBH

Related pharmaceutical patents in our USPTO index.

  1. US 7585852

    Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation

    Solidago AG · Expires Sep 3, 2029

    granted

Frequently asked questions

What is US patent 11172694?

US 11172694 (Core-shell structure with titanium dioxide core) is held by SOLID CHEMICALS GMBH. Status: granted. Granted Nov 16, 2021. Expires Nov 11, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11172694?

SOLID CHEMICALS GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.

When does US 11172694 expire?

Our index shows an expiration date of Nov 11, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.